Author

admin

Browsing

Ramp Metals Inc. (TSXV: RAMP) (‘Ramp Metals’ or the ‘Company’) is pleased to announce that the Company has closed its previously announced non-brokered private placement financing (the ‘Financing’) for total proceeds of $3,464,917.74. Due to investor demand, the Company increased the size of the flow-through portion of the Financing from $2.3M to approximately $3.07M.

In the Financing, Ramp Metals issued and sold an aggregate of 1,481,482 charity flow-through common shares (the ‘CFT Shares‘) at a price of $2.07 per CFT Share, plus 295,000 common shares (the ‘Common Shares‘) at a price of $1.35 per Common Share. No finder’s fees were payable in connection with the Financing.

The Company plans to use the proceeds from the issuance of CFT Shares for critical mineral exploration expenses at the Company’s Rottenstone SW property in Saskatchewan, Canada. The proceeds from the sale of the Common Shares will be used for both exploration expenses and general working capital.

All securities issued in the Financing are subject to a hold period in Canada until September 24, 2025, in accordance with applicable securities laws.

The CFT Shares will qualify as ‘flow-through shares’ (within the meaning of subsection 66(15) of the Income Tax Act (Canada) (the ‘Tax Act‘). An amount equal to the gross proceeds from the issuance of the CFT Shares will be used to incur eligible resource exploration expenses which will qualify as (i) ‘Canadian exploration expenses’ (as defined in the Tax Act), (ii) as ‘flow-through critical mineral mining expenditures’ (as defined in subsection 127(9) of the Tax Act), and (iii) as ‘eligible flow-through mining expenditures’ within the meaning of The Mineral Exploration Tax Credit Regulations, 2014 (Saskatchewan) (collectively, the ‘Qualifying Expenditures‘). Qualifying Expenditures in an aggregate amount not less than the gross proceeds raised from the issuance of the CFT Shares will be incurred (or deemed to be incurred) by the Company on or before December 31, 2026 and will be renounced by the Company to the initial subscribers of the CFT Shares with an effective date no later than December 31, 2025.

The closing of the Financing remains subject to the approval of the TSX Venture Exchange.

About Ramp Metals Inc.

Ramp Metals is a grassroots exploration company with a focus on a potential new Saskatchewan gold district. The Company currently has new high-grade gold discovery of 73.55 g/t Au over 7.5m at its flagship Rottenstone SW property. The Rottenstone SW property comprises 32,715 hectares and is situated in the Rottenstone Domain.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

FORWARD-LOOKING STATEMENTS

This news release contains ‘forward-looking statements’ within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking statements. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as ‘plans’, ‘expects’ or ‘does not expect’, ‘is expected’, ‘budget’, ‘scheduled’, ‘estimates’, ‘forecasts’, ‘intends’, ‘anticipates’ or ‘does not anticipate’, or ‘believes’, or variations of such words and phrases or may contain statements that certain actions, events or results ‘may’, ‘could’, ‘would’, ‘might’ or ‘will be taken’, ‘will continue’, ‘will occur’ or ‘will be achieved’. The forward-looking information and forward-looking statements contained herein include, but are not limited to, statements regarding the completion of the Financing, the use of proceeds therefrom, and the Company’s exploration activities.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: requirements for additional capital; future prices of minerals; changes in general economic conditions; changes in the financial markets and in the demand and market price for commodities; other risks of the mining industry; the inability to obtain any necessary governmental and regulatory approvals; changes in laws, regulations and policies affecting mining operations; hedging practices; and currency fluctuations.

Although the Company has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements or information. No forward-looking statement can be guaranteed. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and the Company does not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

For further information, please contact:

Ramp Metals Inc.

Jordan Black
Chief Executive Officer
jordaneblack@rampmetals.com

Prit Singh
Director
905 510 7636

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/253365

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

/NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRE SERVICES/

finlay minerals ltd. (TSXV: FYL) (OTCQB: FYMNF ) (‘Finlay’ or the ‘Company’) is pleased to announce that it intends to complete a non-brokered private placement (the ‘ Private Placement ‘) consisting of the issuance of any combination of: (i) common shares of the Company to be issued on a flow-through basis under the Income Tax Act ( Canada ) (each, a ‘ FT Share ‘) at a price of $0.11 per FT Share, and (ii) non-flow-through units of the Company (each, a ‘ NFT Unit ‘) at a price of $0.10 per NFT Unit, for aggregate gross proceeds to the Company of up to $1,000,000 . The Private Placement is subject to a minimum offering amount of $500,000 to be raised through any combination of FT Shares and NFT Units.

Each NFT Unit will be comprised of one non-flow-through common share of the Company (each, a ‘ NFT Share ‘) and one non-flow-through common share purchase warrant (a ‘ Warrant ‘). Each Warrant will be exercisable by the holder thereof to acquire one NFT Share at an exercise price of $0.20 per NFT Share for a period of two years from the date of issuance of the Warrant (the ‘ Warrant Expiry Date ‘), subject to acceleration. The Warrant Expiry Date may, at the Company’s sole discretion, be accelerated if at any time following the Closing Date (as defined herein), the common shares of the Company trade at a daily volume-weighted average trading price above $0.30 per common share for a period of 30 consecutive trading days on the TSX Venture Exchange (the ‘ TSXV ‘) or on such other stock exchange where the majority of the trading occurs (the ‘ Trading Target ‘) and the Company provides notice to the Warrant holders by way of press release announcing that such Trading Target has been achieved, provided that the accelerated expiry date of the Warrants falls on the earlier of (unless exercised by the holder prior to such date) (the ‘ Accelerated Expiry Date ‘): (i) the 30th day after the Company provides notice to the Warrant holders of its intention to accelerate the Warrant Expiry Date; and (ii) the Warrant Expiry Date. The failure of the Company to give notice in respect of a Trading Target will not preclude the Company from giving notice of any subsequent Trading Target. All Warrants that remain unexercised following the Accelerated Expiry Date shall immediately expire and all rights of holders of such Warrants shall be terminated without any compensation to such holders.

The Company intends to use the gross proceeds of the Private Placement for exploration of the Company’s SAY, JJB and Silver Hope properties, and for general working capital purposes. The Company will use the gross proceeds from the issuance of FT Shares to incur ‘Canadian exploration expenses’ and qualify as ‘flow-through mining expenditures’, as such terms are defined in the Income Tax Act ( Canada ).

Subject to compliance with applicable regulatory requirements, the Private Placement is being conducted pursuant to the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions and in reliance on the Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption . The securities issued to purchasers in the Private Placement will not be subject to a hold period under applicable Canadian securities laws. There is an offering document related to the Private Placement that can be accessed under the Company’s profile at www.sedarplus.ca and on the Company’s website at www.finlayminerals.com . Prospective investors should read this offering document before making an investment decision.

The closing of the Private Placement is expected to occur on or about June 9, 2025 (the ‘ Closing Date ‘). The closing of the Private Placement is subject to certain closing conditions, including the approval of the TSXV. The Company may pay finder’s fees in cash and securities to certain arm’s length finders engaged in connection with the Private Placement, subject to the approval of the TSXV.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. The securities have not been registered under the United States Securities Act of 1933 , as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements thereunder.

About finlay minerals ltd.

Finlay is a TSXV company focused on exploration for base and precious metal deposits through the advancement of its ATTY, PIL, JJB, SAY and Silver Hope Properties; these properties host copper-gold porphyry and gold-silver epithermal targets within different porphyry districts of northern and central BC. Each property is located in areas of recent development and porphyry discoveries with the advantage of hosting the potential for new discoveries.

Finlay trades under the symbol ‘FYL’ on the TSXV and under the symbol ‘FYMNF’ on the OTCQB. For further information and details, please visit the Company’s website at www.finlayminerals.com

On behalf of the Board of Directors,

Robert F. Brown ,
Executive Chairman of the Board & Director

Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information: This news release includes certain ‘forward-looking information’ and ‘forward-looking statements’ (collectively, ‘forward-looking statements’) within the meaning of applicable Canadian securities legislation. All statements in this news release that address events or developments that we expect to occur in the future are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, although not always, identified by words such as ‘expect’, ‘plan’, ‘anticipate’, ‘project’, ‘target’, ‘potential’, ‘schedule’, ‘forecast’, ‘budget’, ‘estimate’, ‘intend’ or ‘believe’ and similar expressions or their negative connotations, or that events or conditions ‘will’, ‘would’, ‘may’, ‘could’, ‘should’ or ‘might’ occur. All such forward-looking statements are based on the opinions and estimates of management as of the date such statements are made. Forward-looking statements in this news release include statements regarding, among others, the terms and completion of the Private Placement, raising the minimum and maximum amounts of the Private Placement, the payment of finder’s fees and issuance of finder’s securities, the anticipated closing date and the planned use of proceeds for the Private Placement. Although Finlay believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include the ability to obtain regulatory approval for the Private Placement, the state of equity markets in Canada and other jurisdictions, market prices, exploration successes, and continued availability of capital and financing and general economic, market or business conditions. These forward-looking statements are based on a number of assumptions including, among other things, assumptions regarding general business and economic conditions, the timing and receipt of regulatory and governmental approvals, the ability of Finlay and other parties to satisfy stock exchange and other regulatory requirements in a timely manner, the availability of financing for Finlay’s proposed transactions and programs on reasonable terms, and the ability of third-party service providers to deliver services in a timely manner. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements,   and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. Finlay does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future or otherwise, except as required by applicable law.

SOURCE finlay minerals ltd.

View original content to download multimedia: http://www.newswire.ca/en/releases/archive/May2025/26/c7629.html

News Provided by Canada Newswire via QuoteMedia

This post appeared first on investingnews.com

Gold Price Surge Hits $3,385 Amid Trade Tensions

The gold price surge continued on April 21, 2025, as gold hit a record high of $3,385 per ounce. This milestone came amid a weakening U.S. dollar and renewed global trade tensions. Investors are increasingly turning to gold as a safe-haven asset, signaling market uncertainty and shifting investment strategies.

Gold Price Increase Driven by Dollar Weakness

The U.S. dollar index fell sharply, hitting its lowest level since January 2024. A weaker dollar typically boosts gold prices, as it makes the metal more attractive to international buyers. This contributed significantly to the ongoing gold price surge seen in recent weeks.

In addition, economic data indicating slower growth in key global markets has prompted investors to reduce their exposure to riskier assets. Gold’s long-standing reputation as a hedge against economic uncertainty has once again proven true.

Trade Tensions Fuel Demand for Safe-Haven Assets

Ongoing trade friction between major economies—particularly the U.S. and China—has triggered market anxiety. Announcements related to new tariffs and supply chain risks are further motivating the shift from equities to gold. This environment is ideal for a gold price surge to gain momentum.

Analysts Predict Continued Gold Price Growth

Market analysts suggest that the upward trend is far from over. If inflation persists and interest rates remain steady or fall, the gold price could climb even higher. Some predict that the next psychological barrier of $3,500 per ounce may soon be tested.

As the global economic landscape continues to evolve, gold is expected to remain a central pillar in investor portfolios. Whether as a hedge against inflation or a response to geopolitical unrest, the gold price surge is being closely monitored by financial experts.

Source: Yahoo Finance

Related: Market Insights | Commodity News

The post Gold Price Surge Hits $3,385 Amid Trade Tensions appeared first on FinanceBrokerage.

BNB Price Surge Leads Crypto Gains as Bitcoin Climbs

The BNB price surge on April 21, 2025, stole the spotlight as Binance Coin jumped over 3.2% to cross the $600 mark. This move came as Bitcoin soared past $87,000, reigniting investor interest in altcoins. The bullish wave didn’t stop with BNB—SOL and XRP also made strong moves, reflecting a positive trend across the cryptocurrency market.

BNB Price Surge Driven by Token Burn and Momentum

Fueling the BNB price surge was Binance’s recent $1 billion token burn, which reduced the circulating supply. Additionally, increased trading volumes and renewed faith in Binance’s ecosystem helped BNB regain upward momentum. Investors are optimistic that Binance’s expansion and focus on compliance could drive long-term growth.

SOL Rally and XRP Breakout Add to Market Optimism

Solana (SOL) saw a 10.2% rally, breaking above the $135 resistance level with strong volume and technical confirmation. XRP, on the other hand, climbed past $2.10, setting the stage for a potential breakout above $2.15. These moves indicate bullish setups that are gaining attention from both traders and long-term holders.

Bitcoin Reinforces Its Role as Digital Gold

Bitcoin’s rise above $87,000 reflects renewed demand for a digital safe-haven. With increasing global economic uncertainty and inflation concerns, many investors view Bitcoin as “digital gold.” This sentiment is spilling over into altcoins, triggering the current crypto rally.

Conclusion and Market Outlook

The BNB price surge highlights growing investor confidence in altcoins. Alongside Bitcoin’s strength, tokens like SOL and XRP are enjoying increased attention. If this trend continues, more gains could be ahead for altcoin markets. Investors should monitor resistance levels and trading volumes closely for signs of sustained momentum.

Source: Yahoo Finance

Related: Crypto Updates | Market Trends

The post BNB Price Surge Leads Crypto Gains as Bitcoin Climbs appeared first on FinanceBrokerage.

Buy Bitcoin Under $100K Before The Next Bull Run

The opportunity to buy Bitcoin under $100K may not last much longer. On April 21, 2025, Bitcoin (BTC) traded just below the $100,000 mark, a price level many analysts believe could be the last stop before a massive new rally begins. With institutional adoption rising and macroeconomic pressures easing, the case for long-term BTC growth is strengthening.

Why Now Might Be the Time to Buy Bitcoin Under $100K

Market experts point to several factors fueling the bullish sentiment. Firstly, Bitcoin’s halving event earlier this year significantly reduced block rewards, cutting daily supply by half. Historically, halving events have preceded major bull runs. Secondly, growing interest from ETFs and institutional players is creating steady buying pressure. Lastly, declining inflation and improved global liquidity conditions are encouraging investment in risk assets like Bitcoin.

According to Bitwise CIO Matt Hougan, “It’s not too late to buy Bitcoin under $100K. This could be one of the last best opportunities before we see a surge well beyond six figures.”

Long-Term Outlook for BTC Investors

Looking ahead, many analysts predict that Bitcoin could exceed $150,000 by the end of the year. While this isn’t guaranteed, trends in institutional adoption, limited supply, and rising use cases for Bitcoin suggest that prices may continue climbing.

Although short-term volatility persists, long-term investors remain focused on fundamentals. If history repeats itself, buying Bitcoin at sub-$100K levels may prove to be a decision rewarded in the coming cycle.

Final Thoughts

If you’ve been on the sidelines, now could be your moment to enter the market. The chance to buy Bitcoin under $100K might not last much longer. As always, do your research and consider your financial goals before investing.

Source: Yahoo Finance

Related: Bitcoin News | Crypto Analysis

The post Buy Bitcoin Under $100K Before The Next Bull Run appeared first on FinanceBrokerage.

Trump’s Fed Criticism Sparks Investor Concerns

The recent spotlight on Trump’s Fed Criticism has sparked unease among investors and financial analysts alike. President Donald Trump’s repeated public attacks on Federal Reserve Chair Jerome Powell have amplified concerns over the central bank’s independence. As a result, markets have reacted with volatility, and investor sentiment has taken a noticeable hit.

Market Reactions to Political Pressure

Wall Street’s response to Trump’s Fed Criticism was swift. Major stock indices, including the S&P 500 and Nasdaq, posted losses amid uncertainty over future monetary policy decisions. Investors fear that political attempts to sway the Federal Reserve’s agenda may undermine its objectivity. If monetary policy is dictated by short-term political goals rather than long-term economic data, the implications could be severe for inflation, interest rates, and overall economic health.

Why Federal Reserve Independence Matters

One of the cornerstones of a stable economy is a politically neutral central bank. Trump’s Fed Criticism has called that neutrality into question. The Federal Reserve must be able to act without external pressure to maintain credibility in the eyes of global markets. Political interference could compromise its ability to control inflation or manage unemployment rates effectively.

Investor Sentiment and Future Outlook

Investor confidence remains fragile. Many market participants have shifted assets into safer investments such as gold and U.S. treasuries, seeking shelter from potential turmoil. Economic advisors stress the importance of maintaining clear, data-driven policy guidance, especially as the U.S. navigates ongoing trade issues and inflation concerns.

In the coming weeks, the Federal Reserve’s actions will be closely watched. Should Trump’s Fed Criticism intensify, it could further erode market stability and investor trust in U.S. monetary policy.

Source: Yahoo Finance

 

The post Trump’s Fed Criticism Sparks Investor Concerns appeared first on FinanceBrokerage.

Oil Prices Rebound After Trump’s Criticism of Fed Chair Powell

On April 22, 2025, oil prices rebound experienced a modest rebound following a significant drop the previous day. The initial decline was triggered by President Donald Trump’s renewed criticism of Federal Reserve Chair Jerome Powell, which unsettled financial markets and raised concerns about the central bank’s independence.

Market Reaction to Political Commentary

President Trump’s comments on Monday intensified investor fears regarding the Federal Reserve’s autonomy in setting monetary policy. The criticism led to a broad sell-off in equities and commodities, with oil prices bearing the brunt of the market’s anxiety.

Short-Covering Leads to Price Recovery

Despite the initial plunge, oil prices rebound edged higher on Tuesday as investors engaged in short-covering. Brent crude futures rose 0.5% to $66.62 per barrel, while West Texas Intermediate (WTI) crude for May delivery increased by 1% to $63.73 per barrel. The more actively traded WTI June contract also gained 0.7% to $62.84 per barrel.

Ongoing Economic Concerns

Market participants remain cautious amid ongoing fears of a potential recession linked to U.S. tariff policies and concerns over Federal Reserve independence. These factors have increased worries about the U.S. economy and crude demand. Additionally, progress in U.S.-Iran nuclear deal talks has eased supply concerns, potentially impacting oil prices further.

As the situation evolves, investors will closely monitor geopolitical developments and central bank communications to assess the potential long-term impacts on the energy markets.

Source: BloomBurg

The post Oil Prices Rebound After Trump’s Criticism of Powell appeared first on FinanceBrokerage.

It took six months, countless hours on hold and intervention from state regulators before Sue Cover says she finally resolved an over $1,000 billing dispute with UnitedHealthcare in 2023.

Cover, 46, said she was overbilled for emergency room visits for her and her son, along with a standard ultrasound. While Cover said her family would eventually have been able to pay the sum, she said it would have been a financial strain on them.

Cover, a San Diego benefits advocate, said she had conversations with UnitedHealthcare that “felt like a circular dance.” Cover said she picked through dense policy language and fielded frequent calls from creditors. She said the experience felt designed to exhaust patients into submission.

“It sometimes took my entire day of just sitting on the phone, being on hold with the hospital or the insurance company,” Cover said.

Cover’s experience is familiar to many Americans. And it embodies rising public furor toward insurers and in particular UnitedHealthcare, the largest private health insurer in the U.S., which has become the poster child for problems with the U.S. insurance industry and the nation’s sprawling health-care system.

The company and other insurers have faced backlash from patients who say they were denied necessary care, providers who say they are buried in red tape and lawmakers who say they are alarmed by its vast influence.

UnitedHealthcare in a statement said it is working with Cover’s provider to “understand the facts of these claims.” The company said it is “unfortunate that CNBC rushed to publish this story without allowing us and the provider adequate time to review.” CNBC provided the company several days to review Cover’s situation before publication.

Andrew Witty, CEO of UnitedHealthcare’s company, UnitedHealth Group, stepped down earlier this month for what the company called “personal reasons.” Witty had led the company through the thick of public and investor blowback. The insurer also pulled its 2025 earnings guidance this month, partly due to rising medical costs, it said.

UnitedHealth Group is by far the biggest company in the insurance industry by market cap, worth nearly $275 billion. It controls an estimated 15% of the U.S. health insurance market, serving more than 29 million Americans, according to a 2024 report from the American Medical Association. Meanwhile, competitors Elevance Health and CVS Health control an estimated 12% of the market each.

It’s no surprise that a company with such a wide reach faces public blowback. But the personal and financial sensitivity of health care makes the venom directed at UnitedHealth unique, some experts told CNBC.

Shares of UnitedHealth Group are down about 40% this year following a string of setbacks for the company, despite a temporary reprieve sparked in part by share purchases by company insiders. In the last month alone, UnitedHealth Group has lost nearly $300 billion of its $600 billion market cap following Witty’s exit, the company’s rough first-quarter earnings and a reported criminal probe into possible Medicare fraud.

In a statement about the investigation, UnitedHealth Group said, “We stand by the integrity of our Medicare Advantage program.”

Over the years, UnitedHealthcare and other insurers have also faced numerous patient and shareholder lawsuits and several other government investigations.

UnitedHealth Group is also contending with the fallout from a February 2024 ransomware attack on Change Healthcare, a subsidiary that processes a significant portion of the country’s medical claims.

More recently, UnitedHealthcare became a symbol for outrage toward insurers following the fatal shooting of its CEO, Brian Thompson, in December. Thompson’s death reignited calls to reform what many advocates and lawmakers say is an opaque industry that puts profits above patients.

The problems go deeper than UnitedHealth Group: Insurers are just one piece of what some experts call a broken U.S. health-care system, where many stakeholders, including drugmakers and pharmacy benefit managers, are trying to balance patient care with making money. Still, experts emphasized that insurers’ cost-cutting tactics — from denying claims to charging higher premiums — can delay or block crucial treatment, leave patients with unexpected bills, they say, or in some cases, even mean the difference between life and death.

In a statement, UnitedHealthcare said it is unfortunate that CNBC appears to be drawing broad conclusions based on a small number of anecdotes.”

Frustration with insurers is a symptom of a broader problem: a convoluted health-care system that costs the U.S. more than $4 trillion annually.

U.S. patients spend far more on health care than people anywhere else in the world, yet have the lowest life expectancy among large, wealthy countries, according to the Commonwealth Fund, an independent research group. Over the past five years, U.S. spending on insurance premiums, out-of-pocket co-payments, pharmaceuticals and hospital services has also increased, government data show.

While many developed countries have significant control over costs because they provide universal coverage, the U.S. relies on a patchwork of public and private insurance, often using profit-driven middlemen to manage care, said Howard Lapin, adjunct professor at the University of Illinois Chicago School of Law.

But the biggest driver of U.S. health spending isn’t how much patients use care — it’s prices, said Richard Hirth, professor of health management and policy at the University of Michigan.

There is “unbelievable inflation of the prices that are being charged primarily by hospitals, but also drug companies and other providers in the system,” said Sabrina Corlette, co-director of the Center on Health Insurance Reforms at Georgetown University.

Lapin said factors such as overtreatment, fraud, health-care consolidation and administrative overhead raise costs for payers and providers, who then pass those on through higher prices. U.S. prescription drug prices are also two to three times higher than those in other developed countries, partly due to limited price regulation and pharmaceutical industry practices such as patent extensions.

While patients often blame insurers, the companies are only part of the problem. Some experts argue that eliminating their profits wouldn’t drastically lower U.S. health-care costs.

Still, UnitedHealthcare and other insurers have become easy targets for patient frustration — and not without reason, according to industry experts.

Their for-profit business model centers on managing claims to limit payouts, while complying with regulations and keeping customers content. That often means denying services deemed medically unnecessary, experts said. But at times, insurers reject care that patients need, leaving them without vital treatment or saddled with hefty bills, they added.

Insurers use tools such as deductibles, co-pays, and prior authorization — or requiring approval before certain treatments — to control costs. Industry experts say companies are increasingly relying on artificial intelligence to review claims, and that can sometimes lead to inaccurate denials.

“It’s all part of the same business model — to avoid paying as many claims as possible in a timely fashion,” said Dylan Roby, an affiliate at the UCLA Center for Health Policy Research.

While other private U.S. insurers employ many of the same tactics, UnitedHealth Group appears to have faced the most public backlash due to its size and visibility.

UnitedHealth Group’s market value dwarfs the sub-$100 billion market caps of competitors such as CVS, Cigna and Elevance. UnitedHealth Group booked more than $400 billion in revenue in 2024 alone, up from roughly $100 billion in 2012.

It has expanded into many parts of the health-care system, sparking more criticism of other segments of its business — and the company’s ability to use one unit to benefit another.

UnitedHealth Group grew by buying smaller companies and building them into its growing health-care business. The company now serves nearly 150 million people and controls everything from insurance and medical services to sensitive health-care data.

UnitedHealth Group owns a powerful pharmacy benefit manager, or PBM, called Optum Rx, which gives it even more sway over the market.

PBMs act as middlemen, negotiating drug rebates on behalf of insurers, managing lists of drugs covered by health plans and reimbursing pharmacies for prescriptions. But lawmakers and drugmakers accuse them of overcharging plans, underpaying pharmacies and failing to pass savings on to patients.

Owning a PBM gives UnitedHealth Group control over both supply and demand, Corlette said. Its insurance arm influences what care is covered, while Optum Rx determines what drugs are offered and at what price. UnitedHealth Group can maximize profits by steering patients to lower-cost or higher-margin treatments and keeping rebates, she said.

The company’s reach goes even further, Corlette added: Optum Health now employs or affiliates with about 90,000 doctors — nearly 10% of U.S. physicians — allowing UnitedHealth Group to direct patients to its own providers and essentially pay itself for care.

A STAT investigation last year found that UnitedHealth uses its physicians to squeeze profits from patients. But the company in response said its “providers and partners make independent clinical decisions, and we expect them to diagnose and document patient information completely and accurately in compliance with [federal] guidelines.”

Other insurers, such as CVS and Cigna, also own large PBMs and offer care services. But UnitedHealth Group has achieved greater scale and stronger financial returns.

“I think the company is certainly best in class when it comes to insurers, in terms of providing profits for shareholders,” said Roby. “But people on the consumer side probably say otherwise when it comes to their experience.”

No one knows exactly how often private insurers deny claims, since they aren’t generally required to report that data. But some analyses suggest that UnitedHealthcare has rejected care at higher rates than its peers for certain types of plans.

A January report by nonprofit group KFF found that UnitedHealthcare denied 33% of in-network claims across Affordable Care Act plans in 20 states in 2023, one of the highest rates among major insurers. CVS denied 22% of claims across 11 states, and Cigna denied 21% in eight states.

UnitedHealth did not respond to a request for comment on that report. But in December, the company also pushed back on public criticism around its denial rates, saying it approves and pays about 90% of claims upon submission. UnitedHealthcare’s website says the remaining 10% go through an additional review process. The company says its claims approval rate stands at 98% after that review.

In addition, UnitedHealth Group is facing lawsuits over denials. In November, families of two deceased Medicare Advantage patients sued the company and its subsidiary, alleging it used an AI model with a “90% error rate” to deny their claims. UnitedHealth Group has argued it should be dismissed from the case because the families didn’t complete Medicare’s appeals process.

A spokesperson for the company’s subsidiary, NaviHealth, also previously told news outlets that the lawsuit “has no merit” and that the AI tool is used to help providers understand what care a patient may need. It does not help make coverage decisions, which are ultimately based on the terms of a member’s plan and criteria from the Centers for Medicare & Medicaid Services, the spokesperson said.

Meanwhile, the reported Justice Department criminal probe outlined by the Wall Street Journal targets the company’s Medicare Advantage business practices. In its statement, the company said the Justice Department has not notified it about the reported probe, and called the newspaper’s reporting “deeply irresponsible.”

Inside the company, employees say customers and workers alike face hurdles.

One worker, who requested anonymity for fear of retaliation, said UnitedHealthcare’s provider website often includes doctors listed as in-network or accepting new patients when they’re not, leading to frequent complaints. Management often replies that it’s too difficult to keep provider statuses up to date, the person said.

UnitedHealthcare told CNBC it believes “maintaining accurate provider directories is a shared responsibility among health plans and providers,” and that it “proactively verifies provider data on a regular basis.” The vast majority of all inaccuracies are due to errors or lack of up-to-date information submitted by providers, the company added.

Emily Baack, a clinical administrative coordinator at UMR, a subsidiary of UnitedHealthcare, criticized the length of time it can take a provider to reach a real support worker over the phone who can help assess claims or prior authorization requests. She said the company’s automated phone system can misroute people’s calls or leave them waiting for a support person for over an hour.

But Baack emphasized that similar issues occur across all insurance companies.

She said providers feel compelled to submit unnecessary prior authorization requests out of fear that claims won’t be paid on time. Baack said that leads to a massive backlog of paperwork on her end and delays care for patients.

UnitedHealthcare said prior authorization is “an important checkpoint” that helps ensure members are receiving coverage for safe and effective care.

The company noted it is “continually taking action to simplify and modernize the prior authorization process.” That includes reducing the number of services and procedures that require prior authorization and exempting qualified provider groups from needing to submit prior authorization requests for certain services.

While UnitedHealthcare is not the only insurer facing criticism from patients, Thompson’s killing in December reinforced the company’s unique position in the public eye. Thousands of people took to social media to express outrage toward the company, sharing examples of their own struggles.

The public’s hostile reaction to Thompson’s death did not surprise many industry insiders.

Alicia Graham, co-founder and chief operating officer of the startup Claimable, said Thompson’s murder was “a horrible crime.” She also acknowledged that anger has been bubbling up in various online health communities “for years.”

Claimable is one of several startups trying to address pain points within insurance. It’s not an easy corner of the market to enter, and many of these companies, including Claimable, have been using the AI boom to their advantage.

Claimable, founded in 2024, said it helps patients challenge denials by submitting customized, AI-generated appeal letters on their behalf. The company can submit appeals for conditions such as migraines and certain pediatric and autoimmune diseases, though Graham said it is expanding those offerings quickly.

Many patients aren’t aware that they have a right to appeal, and those who do can spend hours combing through records to draft one, Graham said. If patients are eligible to submit an appeal letter through Claimable, she said they can often do so in minutes. Each appeal costs users $39.95 plus shipping, according to the company’s website.

“A lot of patients are afraid, a lot of patients are frustrated, a lot of patients are confused about the process, so what we’ve tried to do is make it all as easy as possible,” Graham told CNBC.

Some experts have warned about the possibility of health-care “bot wars,” where all parties are using AI to try to gain an edge.

Mike Desjadon, CEO of the startup Anomaly, said he’s concerned about the potential for an AI arms race in the sector, but he remains optimistic. Anomaly, founded in 2020, uses AI to help providers determine what insurers are and aren’t paying for in advance of care, he said.

“I run a technology company and I want to win, and I want our customers to win, and that’s all very true, but at the same time, I’m a citizen and a patient and a husband and a father and a taxpayer, and I just want health care to be rational and be paid for appropriately,” Desjadon told CNBC.

Dr. Jeremy Friese, founder and CEO of the startup Humata Health, said patients tend to interact with insurers only once something goes wrong, which contributes to their frustrations. Requirements such as prior authorization can be a “huge black box” for patients, but they’re also cumbersome for doctors, he said.

Friese said his business was inspired by his work as an interventional radiologist. In 2017, he co-founded a prior-authorization company called Verata Health, which was acquired by the now-defunct health-care AI startup Olive. Friese bought back his technology and founded his latest venture, Humata, in 2023.

Humata uses AI to automate prior authorization for all specialties and payers, Friese said. The company primarily works with medium and large health systems, and it announced a $25 million funding round in June.

“There’s just a lot of pent-up anger and angst, frankly, on all aspects of the health-care ecosystem,” Friese told CNBC.

UnitedHealth Group also set a grim record last year that did little to help public perception. The company’s subsidiary Change Healthcare suffered a cyberattack that affected around 190 million Americans, the largest reported health-care data breach in U.S. history.

Change Healthcare offers payment and revenue cycle management tools, as well as other solutions, such as electronic prescription software. In 2022, it merged with UnitedHealth Group’s Optum unit, which touches more than 100 million patients in the U.S.

In February 2024, a ransomware group called Blackcat breached part of Change Healthcare’s information technology network. UnitedHealth Group isolated and disconnected the affected systems “immediately upon detection” of the threat, according to a filing with the U.S. Securities and Exchange Commission, but the ensuing disruption rocked the health-care sector.

Money stopped flowing while the company’s systems were offline, so a major revenue source for thousands of providers across the U.S. screeched to a halt. Some doctors pulled thousands of dollars out of their personal savings to keep their practices afloat.

“It was and remains the largest and most consequential cyberattack against health care in history,” John Riggi, the national advisor for cybersecurity and risk at the American Hospital Association, told CNBC.

Ransomware is a type of malicious software that blocks victims from accessing their computer files, systems and networks, according to the Federal Bureau of Investigation. Ransomware groups such as Blackcat, which are often based in countries such as Russia, China and North Korea, will deploy this software, steal sensitive data and then demand a payment for its return.

Ransomware attacks within the health-care sector have climbed in recent years, in part because patient data is valuable and relatively easy for cybercriminals to exploit, said Steve Cagle, CEO of the health-care cybersecurity and compliance firm Clearwater.

“It’s been a very lucrative and successful business for them,” Cagle told CNBC. “Unfortunately, we’ll continue to see that type of activity until something changes.”

UnitedHealth Group paid the hackers a $22 million ransom to try to protect patients’ data, then-CEO Witty said during a Senate hearing in May 2024.

In March 2024, UnitedHealth Group launched a temporary funding assistance program to help providers with short-term cash flow.

The program got off to a rocky start, several doctors told CNBC, and the initial deposits did not cover their mounting expenses.

UnitedHealth Group ultimately paid out more than $9 billion to providers in 2024, according to the company’s fourth-quarter earnings report in January.

Witty said in his congressional testimony that providers would only be required to repay the loans when “they, not me, but they confirm that their cash flow is normalized.”

Almost a year later, however, the company is aggressively going after borrowers, demanding they “immediately repay” their outstanding balances, according to documents viewed by CNBC and providers who received funding. Some groups have been asked to repay hundreds of thousands of dollars in a matter of days, according to documents viewed by CNBC.

A spokesperson for Change Healthcare confirmed to CNBC in April that the company has started recouping the loans.

We continue to work with providers on repayment and other options, and continue to reach out to those providers that have not been responsive to previous calls or email requests for more information,” the spokesperson said.

The pressure for repayment drew more ire toward UnitedHealth Group on social media, and some providers told CNBC that dealing with the company was a “very frustrating experience.”

The vast majority of Change Healthcare’s services have been restored over the last year, but three products are still listed as “partial service available,” according to UnitedHealth’s cyberattack response website.

Witty’s departure and the company’s warning about elevated medical costs, combined with the fallout from Thompson’s murder and the Change Healthcare cyberattack, could mean UnitedHealth faces an uphill battle.

UnitedHealth Group appears to be trying to regain the public’s trust. For example, Optum Rx in March announced plans to eliminate prior authorizations on dozens of drugs, easing a pain point for physicians and patients.

But policy changes at UnitedHealth Group and other insurers may not drastically improve care for patients, health insurance industry experts previously told CNBC.

They said there will need to be structural changes to the entire insurance industry, which will require legislation that may not be high on the priority list for the closely divided Congress.

The spotlight on UnitedHealth Group may only grow brighter in the coming months. The trial date for Luigi Mangione, the man facing federal stalking and murder charges in connection with Thompson’s shooting, is expected to be set in December. Mangione has pleaded not guilty to the charges.

This post appeared first on NBC NEWS

The Federal Trade Commission voted to dismiss a lawsuit filed in the last days of the Biden administration that accused PepsiCo of offering sweetheart pricing to big retailers.

FTC Chair Andrew Ferguson dissented to the suit when it was filed in January, when he was one of the regulator’s commissioners. Now the agency’s leader, Ferguson on Thursday again criticized the case as “a nakedly political effort to commit this administration to pursuing little more than a hunch that Pepsi had violated the law.”

“The FTC’s outstanding staff will instead get back to work protecting consumers and ensuring a fair and competitive business environment,” he said in a statement.

The FTC voted 3-0 to drop the suit. The panel is supposed to be made up of five commissioners, no more than three of whom can share the same political party. But it is currently led by three Republicans after President Donald Trump fired its two Democratic commissioners in March. The two ousted officials have slammed their removals as illegal and are urging a judge to reinstate them.

Pepsi welcomed the FTC decision Thursday. “PepsiCo has always and will continue to provide all customers with fair, competitive, and non-discriminatory pricing, discounts and promotional value,” a spokesperson said in a statement. Beyond its namesake soda, the company makes an array of snacks and other food products, including Doritos, Rold Gold pretzels and Sabra hummus.

Former FTC Chair Lina Khan, who led the commission when the agency brought its case against Pepsi, criticized the move Thursday as “disturbing behavior” by the agency.

“This lawsuit would’ve protected families from paying higher prices at the grocery store and stopped conduct that squeezes small businesses and communities across America,” she wrote on X Thursday evening. “Dismissing it is a gift to giant retailers as they gear up to hike prices.”

The decision comes little more than a week after top-ranking Democrats on Capitol Hill sent a letter to Pepsi demanding more information about its pricing strategy. They sought to revive a Biden-era focus on price-gouging as a driver of inflation, an argument that has taken a back seat to the Trump administration’s attention on purportedly unfair trade arrangements.

But major corporations continue to draw scrutiny from the White House over pricing in other ways. Last weekend, Trump slammed Walmart for warning that it was likely to raise prices to offset the costs of his import taxes, demanding on social media that it “EAT THE TARIFFS.”

In the days since then, other major consumer brands have appeared to tread cautiously around pricing. Target said Wednesday that charging customers more would be its “very last resort.” Home Depot virtually ruled out price hikes this week, and Lowe’s barely mentioned tariff impacts in its Wednesday earnings call at all.

CORRECTION (May 22, 2025, 8:45 p.m. ET): Due to an editing error, a previous version of this article misstated when congressional Democrats sent their letter to Pepsi. It was on May 11, not last weekend.

This post appeared first on NBC NEWS

United Airlines reached an “industry-leading” tentative labor deal for its 28,000 flight attendants, their union said Friday.

The deal includes “40% of total economic improvements” in the first year and retroactive pay, a signing bonus, and quality of life improvements, like better scheduling and on-call time, the Association of Flight Attendants-CWA said.

The union did not provide further details about the deal.

United flight attendants have not had a raise since 2020.

The cabin crew members voted last year to authorize the union to strike if a deal wasn’t reached. They had also sought federal mediation in negotiations.

U.S. flight attendants have pushed for wage increases for years after pilots and other work groups secured new labor deals in the wake of the pandemic. United is the last of the major U.S. carriers to get a deal done with its flight attendants.

The deal must still face a vote by flight attendants, and contract language will be finalized in the coming days, United said.

This post appeared first on NBC NEWS